KETOROLAC TROMETHAMINE solution

Ketorolac Tromethamine by

Drug Labeling and Warnings

Ketorolac Tromethamine by is a Prescription medication manufactured, distributed, or labeled by SOLA Pharmaceuticals, LLC. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    Ketorolac tromethamine ophthalmic solution is indicated for the temporary relief of ocular itching due to seasonal allergic conjunctivitis. Ketorolac tromethamine ophthalmic solution is also indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction.

  • 2 DOSAGE AND ADMINISTRATION

    2.1 Recommended Dosing

    Patient Dosing

    The recommended dose of ketorolac tromethamine ophthalmic solution is one drop four times a day to the affected eye(s) for relief of ocular itching due to seasonal allergic conjunctivitis.

    For the treatment of postoperative inflammation in patients who have undergone cataract extraction, one drop of ketorolac tromethamine ophthalmic solution should be applied to the affected eye four times daily beginning 24 hours after cataract surgery and continuing through the first 2 weeks of the postoperative period.

    2.2 Use with Other Topical Ophthalmic Medications

    Ketorolac tromethamine ophthalmic solution has been safely administered in conjunction with other ophthalmic medications such as antibiotics, alpha-agonists, beta blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics. Drops should be administered at least 5 minutes apart.

  • 3 DOSAGE FORMS AND STRENGTHS

    5 mL size bottle filled with 3 mL of ketorolac tromethamine ophthalmic solution, 0.5% (5 mg/mL)
    10 mL size bottle filled with 5 mL of ketorolac tromethamine ophthalmic solution, 0.5% (5 mg/mL)
    10 mL size bottle filled with 10 mL of ketorolac tromethamine ophthalmic solution, 0.5% (5 mg/mL)

  • 4 CONTRAINDICATIONS

    Ketorolac tromethamine ophthalmic solution is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formulation.

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Delayed Healing

    Topical nonsteroidal anti-inflammatory drugs (NSAIDs) may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.

    5.2 Cross-Sensitivity or Hypersensitivity

    There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs. There have been reports of bronchospasm or exacerbation of asthma associated with the use of ketorolac tromethamine ophthalmic solution in patients who have either a known hypersensitivity to aspirin/non-steroidal anti-inflammatory drugs or a past medical history of asthma. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.

    5.3 Increased Bleeding Time

    With some NSAIDs, there exists the potential for increased bleeding time due to interference with thrombocyte aggregation. There have been reports that ocularly applied nonsteroidal anti-inflammatory drugs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery.

    It is recommended that ketorolac tromethamine ophthalmic solution be used with caution in patients with known bleeding tendencies or who are receiving other medications, which may prolong bleeding time.

    5.4 Corneal Effects

    Use of topical NSAIDs may result in keratitis. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration, or corneal perforation. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs and should be closely monitored for corneal health.

    Postmarketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients.

    Postmarketing experience with topical NSAIDs also suggests that use more than 1 day prior to surgery or use beyond 14 days post-surgery may increase patient risk for the occurrence and severity of corneal adverse events.

    5.5 Contact Lens Wear

    Ketorolac tromethamine ophthalmic solution should not be administered while wearing contact lenses.

  • 6 ADVERSE REACTIONS

    6.1 Clinical Studies Experience

    Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to the rates in the clinical studies of another drug and may not reflect the rates observed in practice.

    The most frequent adverse reactions reported with the use of ketorolac tromethamine ophthalmic solutions have been transient stinging and burning on instillation. These reactions were reported by up to 40% of patients participating in clinical trials.

    Other adverse reactions occurring approximately 1 to 10% of the time during treatment with ketorolac tromethamine ophthalmic solutions included allergic reactions, corneal edema, iritis, ocular inflammation, ocular irritation, superficial keratitis, and superficial ocular infections.

    Other adverse reactions reported rarely with the use of ketorolac tromethamine ophthalmic solutions included: corneal infiltrates, corneal ulcer, eye dryness, headaches, and visual disturbance (blurry vision).

    6.2 Postmarketing Experience

    The following adverse reactions have been identified during post-marketing use of ketorolac tromethamine ophthalmic solution 0.5% in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to topical ketorolac tromethamine ophthalmic solution 0.5% or a combination of these factors, include bronchospasm or exacerbation of asthma, corneal erosion, corneal perforation, corneal thinning, and epithelial breakdown [see Warnings and Precautions ( 5.2, 5.4)].

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Teratogenic Effects. Pregnancy Category C

    Pregnancy Category C: Ketorolac tromethamine, administered during organogenesis, was not teratogenic in rabbits and rats at oral doses of 3.6 mg/kg/day and 10 mg/kg/day, respectively. These doses are approximately 100 times and 250 times higher respectively than the maximum recommended human topical ophthalmic daily dose of 2 mg (5 mg/ mL x 0.05 mL/drop, x 4 drops x 2 eyes) to affected eyes on a mg/kg basis. Additionally, when administered to rats after Day 17 of gestation at oral doses up to 1.5 mg/kg/day (approximately 40 times the typical human topical ophthalmic daily dose), ketorolac tromethamine resulted in dystocia and increased pup mortality. There are no adequate and well-controlled studies in pregnant women. Ketorolac tromethamine ophthalmic solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

    Nonteratogenic Effects:Because of the known effects of prostaglandin-inhibiting drugs on the fetal cardiovascular system (closure of the ductus arteriosus), the use of ketorolac tromethamine ophthalmic solution during late pregnancy should be avoided.

    8.3 Nursing Mothers

    Because many drugs are excreted in human milk, caution should be exercised when ketorolac tromethamine ophthalmic solution is administered to a nursing woman.

    8.4 Pediatric Use

    Safety and efficacy in pediatric patients below the age of 2 have not been established.

    8.5 Geriatric Use

    No overall clinical differences in safety or effectiveness have been observed between elderly and other adult patients.

  • 11 DESCRIPTION

    Ketorolac tromethamine ophthalmic solution 0.5% is a member of the pyrrolo-pyrrole group of nonsteroidal anti-inflammatory drugs (NSAIDs) for ophthalmic use. Its chemical name is (±)-5-Benzoyl-2, 3-dihydro-1H pyrrolizine-1-carboxylic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) and it has the following structure:

    Structural Formula

    Ketorolac tromethamine ophthalmic solution is supplied as a sterile isotonic aqueous 0.5% solution, with a pH of 7.4. Ketorolac tromethamine ophthalmic solution is a racemic mixture of R-(+) and S-(-) -ketorolac tromethamine. Ketorolac tromethamine may exist in three crystal forms. All forms are equally soluble in water. The pKa of ketorolac is 3.5. This white to off-white crystalline substance discolors on prolonged exposure to light. The molecular weight of ketorolac tromethamine is 376.41. The osmolality of ketorolac tromethamine ophthalmic solution is 290 mOsmol/kg.

    Each mL of ketorolac tromethamine ophthalmic solution contains: Active:ketorolac tromethamine 0.5%. Preservative:benzalkonium chloride 0.01%. Inactives:edetate disodium 0.1%; octoxynol 40; water for injection; sodium chloride; hydrochloric acid and/or sodium hydroxide to adjust the pH.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. The mechanism of its action is thought to be due to its ability to inhibit prostaglandin biosynthesis

    12.3 Pharmacokinetics

    Two drops of 0.5% ketorolac tromethamine ophthalmic solution instilled into the eyes of patients 12 hours and 1 hour prior to cataract extraction achieved a mean ketorolac concentration of 95 ng/mL in the aqueous humor of 8 of 9 eyes tested (range 40 to 170 ng/mL).

    One drop of 0.5% ketorolac tromethamine ophthalmic solution was instilled into 1 eye and 1 drop of vehicle into the other eye TID in 26 healthy subjects. Five (5) of 26 subjects had detectable concentrations of ketorolac in their plasma (range 11 to 23 ng/mL) at Day 10 during topical ocular treatment. The range of concentrations following TID dosing of 0.5% ketorolac tromethamine ophthalmic solution are approximately 4 to 8% of the steady state mean minimum plasma concentration observed following four times daily oral administration of 10 mg ketorolac in humans (290 ± 70 ng/mL).

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Ketorolac tromethamine was not carcinogenic in either rats given up to 5 mg/kg/day orally for 24 months or in mice given 2 mg/kg/day orally for 18 months. These doses are approximately 125 times and 50 times higher respectively than the maximum recommended human topical ophthalmic daily dose given as QID for itching to affected eyes on a mg/kg basis.

    Ketorolac tromethamine was not mutagenic in vitroin the Ames assay or in forward mutation assays. Similarly, it did not result in an in vitroincrease in unscheduled DNA synthesis or an in vivoincrease in chromosome breakage in mice. However, ketorolac tromethamine did result in an increased incidence in chromosomal aberrations in Chinese hamster ovary cells. Ketorolac tromethamine did not impair fertility when administered orally to male and female rats at doses up to 9 mg/kg/day and 16 mg/kg/day, respectively. These doses are respectively 225 and 400 times higher than the typical human topical ophthalmic daily dose.

  • 14 CLINICAL STUDIES

    Two controlled clinical studies showed that ketorolac tromethamine ophthalmic solution was significantly more effective than its vehicle in relieving ocular itching caused by seasonal allergic conjunctivitis.

    Two controlled clinical studies showed that patients treated for two weeks with ketorolac tromethamine ophthalmic solution were less likely to have measurable signs of inflammation (cell and flare) than patients treated with its vehicle.

    Results from clinical studies indicate that ketorolac tromethamine has no significant effect upon intraocular pressure; however, changes in intraocular pressure may occur following cataract surgery.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Ketorolac tromethamine ophthalmic solution 0.5% is supplied sterile, in white opaque plastic LDPE bottles with white droppers, with gray high density polyethylene (HDPE) caps as follows:

    3mL in 5 mL bottle             NDC70512-790-03

    5 mL in 10 mL bottle          NDC70512-790-05

    10 mL in 10 mL bottle        NDC70512-790-10


    Storage:     Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]. Protect from light.

  • 17 PATIENT COUNSELING INFORMATION

    17.1 Slow or Delayed Healing

    Patients should be informed of the possibility that slow or delayed healing may occur while using nonsteroidal anti-inflammatory drugs (NSAIDs).

    17.2 Avoiding Contamination of the Product

    Patients should be instructed to avoid allowing the tip of the bottle to contact the eye or surrounding structures because this could cause the tip to become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

    Also, to avoid the potential for cross-contamination, the patient should be advised to use one bottle for each eye following bilateral ocular surgery. The use of the same bottle of topical eye drops for both eyes following bilateral ocular surgery is not recommended.

    17.3 Contact Lens Wear

    Patients should be advised that ketorolac tromethamine ophthalmic solution should not be administered while wearing contact lenses.

    17.4 Intercurrent Ocular Conditions

    Patients should be advised that if they develop an intercurrent ocular condition (e.g., trauma or infection) or have ocular surgery, they should immediately seek their physician’s advice concerning the continued use of ketorolac tromethamine ophthalmic solution.

    17.5 Concomitant Topical Ocular Therapy

    Patients should be advised that if more than one topical ophthalmic medication is being used, the medicines should be administered at least 5 minutes apart.

    Manufactured for:
    SOLA Pharmaceuticals
    Baton Rouge, LA 70810
    Made in India

    Code: TN/Drugs/TN00003457

    Revised: 03/2024

    22200826

  • PRINCIPAL DISPLAY PANEL

    Principal Display Panel Text for 3mL Container Label:

    NDC: 70512-790-03

    Ketrolac Tromethamine
    Ophthalmic Solution

    0.5%

    FOR TOPICAL OPHTHALMIC USE ONLY

    Sterile

    Rx only          3 mL

    Each mL contains:                  2200820
    Active: ketorolac tromethamine 0.5%.
    Preservative:benzalkonlum chloride 0.01%
    Usual Dosage:One drop four times a day. Refer to
    package insert.
    Storage: Store at 20° - 25°C (68° - 77°F) [See USP 
    Controlled Room Temperature].  Protect from light.
    Manufactured for:
    SOLA Pharmaceuticals
    Baton Rouge, LA 70810
    Made in India

    LOT:

    EXP:

    Code No.:TN/Drugs/TN00003457

    70512-790*03 3ml
  • PRINCIPAL DISPLAY PANEL

    Principal Display Panel Text for 3mL Carton Label:

    NDC: 70512-790-03

    Ketorolac
    Tromethamine
    Opthalmic 
    Solution

    0.5%

    FOR TOPICAL
    OPHTHALMIC USE ONLY

    Sterile

    Rx Only                               3mL

    Each mL contains:

    Active: ketorolac tromethamine 0.5%.

    Preservative: benzalkonlum chloride 0.01%

    Inactives:edetate disodium
    0.1%; octoxynol 40; water for
    injection; sodium chloride; and
    hydrochloric acid and/or sodium
    hydroxide to adjust pH to 7.4.

    Usual Dosage: One drop four times a day. Refer to
    package insert.

    Storage: Store at 20° - 25°C (68° - 77°F)
    [See USP Controlled Room
    Temperature]. 

    Protect from light.

    KEEP OUT OF REACH OF
    CHILDREN

    22200823

    Manufactured for:
    SOLA Pharmaceuticals
    Baton Rouge, LA 70810

    Made in India

    Code No.:TN/Drugs/TN00003457

    3mL Carton

    Principal Display Panel Text for 5mL Container Label:

    NDC: 70512-790-05

    Ketrolac Tromethamine
    Ophthalmic Solution

    0.5%

    FOR TOPICAL OPHTHALMIC USE ONLY

    Sterile

    Rx only          5 mL

    Each mL contains:                  2200831
    Active: ketorolac tromethamine 0.5%.
    Preservative:benzalkonlum chloride 0.01%
    Usual Dosage:One drop four times a day. Refer to
    package insert.
    Storage: Store at 20° - 25°C (68° - 77°F) [See USP 
    Controlled Room Temperature].  Protect from light.
    Note:Bottle filled to 1/2 capacity.
    Manufactured for:
    SOLA Pharmaceuticals
    Baton Rouge, LA 70810
    Made in India

    LOT:

    EXP:

    Code No.:TN/Drugs/TN00003457

    5mL Label

    Principal Display Panel Text for 5mL Carton Label:

    NDC: 70512-790-05

    Ketorolac
    Tromethamine
    Opthalmic
    Solution

    0.5%

    FOR TOPICAL
    OPHTHALMIC USE ONLY

    Sterile

    Rx Only                               5 mL

    Each mL contains:

    Active: ketorolac tromethamine 0.5%.

    Preservative: benzalkonlum chloride 0.01%

    Inactives:edetate disodium
    0.1%; octoxynol 40; water for
    injection; sodium chloride; and
    hydrochloric acid and/or sodium
    hydroxide to adjust pH to 7.4.

    Usual Dosage: One drop four times a day. Refer to
    package insert.

    Storage: Store at 20° - 25°C (68° - 77°F)
    [See USP Controlled Room
    Temperature]. 

    Protect from light.

    KEEP OUT OF REACH OF
    CHILDREN

    Note:Bottle filled to 1/2 capacity.

    22200833

    Manufactured for:
    SOLA Pharmaceuticals
    Baton Rouge, LA 70810

    Made in India

    Code No.:TN/Drugs/TN00003457

    5mL Carton

    Principal Display Panel Text for 10mL Container Label:

    NDC: 70512-790-10

    Ketrolac Tromethamine
    Ophthalmic Solution

    0.5%

    FOR TOPICAL OPHTHALMIC USE ONLY

    Sterile

    Rx only          10 mL

    Each mL contains:                  2200832
    Active: ketorolac tromethamine 0.5%.
    Preservative:benzalkonlum chloride 0.01%
    Usual Dosage:One drop four times a day. Refer to
    package insert.
    Storage: Store at 20° - 25°C (68° - 77°F) [See USP 
    Controlled Room Temperature].  Protect from light.
    Manufactured for:
    SOLA Pharmaceuticals
    Baton Rouge, LA 70810
    Made in India

    LOT:

    EXP:

    Code No.:TN/Drugs/TN00003457

    10mL Label

    Principal Display Panel Text for 10mL Carton Label:

    NDC: 70512-790-10

    Ketorolac
    Tromethamine
    Opthalmic
    Solution

    0.5%

    FOR TOPICAL
    OPHTHALMIC USE ONLY

    Sterile

    Rx Only                               10 mL

    Each mL contains:

    Active: ketorolac tromethamine 0.5%.

    Preservative: benzalkonlum chloride 0.01%

    Inactives:edetate disodium
    0.1%; octoxynol 40; water for
    injection; sodium chloride; and
    hydrochloric acid and/or sodium
    hydroxide to adjust pH to 7.4.

    Usual Dosage: One drop four times a day. Refer to
    package insert.

    Storage: Store at 20° - 25°C (68° - 77°F)
    [See USP Controlled Room
    Temperature]. 

    Protect from light.

    KEEP OUT OF REACH OF
    CHILDREN

    22200834

    Manufactured for:
    SOLA Pharmaceuticals
    Baton Rouge, LA 70810

    Made in India

    Code No.:TN/Drugs/TN00003457

    10mL Carton
  • INGREDIENTS AND APPEARANCE
    KETOROLAC TROMETHAMINE 
    ketorolac tromethamine solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 70512-790
    Route of AdministrationOPHTHALMIC
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    KETOROLAC TROMETHAMINE (UNII: 4EVE5946BQ) (KETOROLAC - UNII:YZI5105V0L) KETOROLAC TROMETHAMINE5 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    BENZALKONIUM CHLORIDE (UNII: F5UM2KM3W7)  
    EDETATE DISODIUM (UNII: 7FLD91C86K)  
    OCTOXYNOL-40 (UNII: 9T1C662FKS)  
    SODIUM CHLORIDE (UNII: 451W47IQ8X)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 70512-790-031 in 1 CARTON04/15/2024
    13 mL in 1 BOTTLE, DROPPER; Type 0: Not a Combination Product
    2NDC: 70512-790-051 in 1 CARTON04/15/2024
    25 mL in 1 BOTTLE, DROPPER; Type 0: Not a Combination Product
    3NDC: 70512-790-101 in 1 CARTON04/15/2024
    310 mL in 1 BOTTLE, DROPPER; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21820404/15/2024
    Labeler - SOLA Pharmaceuticals, LLC (080121345)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.